Skip to main content
OpenTrials
Completed

NCT Number: NCT01595581

Testosterone Administration and ACL Reconstruction in Men

This study is being done to test whether taking testosterone can prevent loss of muscle mass and strength due to anterior cruciate ligament (ACL) reconstructive surgery. Testosterone is the principal male sex hormone and an anabolic (muscle promoting) steroid. It is essential for the development of male reproductive tissues and promotes increased muscle, bone mass, and the growth of body hair.

The investigators hope to learn whether testosterone given before and after ACL reconstructive surgery will increase muscle mass and strength and potentially improve recovery time following surgery.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Overall Objective: The overall objective of this study is to determine if 8 weeks of testosterone first administered 2 weeks prior to surgery, can improve the outcome of anterior cruciate ligament (ACL) reconstruction.

Overall Hypothesis: Standard-of-care rehabilitation with the addition of testosterone administration will augment muscle mass, strength, and physical function following ACL reconstructive surgery compared to standard rehabilitation alone.

Significance: Muscle mass and strength are greatly reduced following ACL surgery. The investigators hypothesize that administration of testosterone will minimize these reductions or potentially increase muscle mass and strength. In doing so, testosterone may hasten a patient's return to physical activity. If testosterone improves recovery after ACL surgery, the same treatment may be used for other injuries that involve trauma and muscle atrophy. Furthermore, this study will examine the effect of trauma with or without testosterone on myogenic regulators in muscle tissue taken during ACL surgery-providing possible mechanistic insights for the clinical outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A complete ACL tear as visualized on MRI
  • The ACL injury can be either "isolated" or combined with one or several of the following injuries visualized on MRI and/or arthroscopy:
  • a meniscus tear that is either left untreated or treated with a partial resection
  • a small, stable meniscus tear treated with fixation, but with the fixation not interfering with the rehabilitation protocol
  • cartilage changes verified on MRI with an arthroscopically determined intact surface.
  • A radiographic examination with normal joint status or combined with either one of the following findings:
  • a small-avulsed fragment located laterally, usually described as a Segond fracture, JSN grade 1 or osteophytes grade 1 as determined by the OARSI atlas15

Exclusion criteria

  • Previous major knee injury or knee surgery
  • Associated posterior cruciate ligament (PCL) or medical collateral ligament (MCL) injury grade III
  • Concomitant severe injury to contra-lateral knee
  • Injury to the lateral/posterolateral ligament complex with significantly increased laxity
  • Unstable longitudinal meniscus tear that requires repair and where the following postoperative treatment (we.e. bracing and limited range of motion) interferes with the rehabilitation protocol
  • Bi-compartmental extensive meniscus resections
  • Cartilage injury representing a full thickness loss down to bone
  • Total rupture of MCL/LCL as visualized on MRI.
  • History of deep vein thrombosis (DVT) or a disorder of the coagulative system
  • Claustrophobia
  • Prior or current use of anabolic steroids
  • General systemic disease affecting physical function
  • Chromosomal disorders
  • Medications that interfere with testosterone production or function, including but not limited to 5α-reductase inhibitors
  • Any other condition or treatment interfering with the completion of the trial

Treatment and study plan

Testosterone

Drug

8 weeks of testosterone administration beginning 2 weeks before ACL surgery

Other names: testosterone enanthate

Placebo

Drug

8 weeks of saline administration beginning 2 weeks before ACL surgery

Other names: saline

Primary outcomes

  1. Changes in Lean Mass

    Time frame: 6, 12, and 24 weeks post operative

    Relative changes in lean mass from 2 weeks prior to surgery to 6 weeks, 12 weeks, and 24 weeks following surgery between the two groups.

Secondary outcomes

  1. KOOS Scores

    Time frame: 6 weeks, 12 weeks, 24 weeks post surgery

    Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) from 2 weeks prior to surgery to 6, 12, and 24 weeks post surgery.

    KOOS is scored from 0 to 100 with 0 representing extreme knee problems and 100 representing normal knee function.

  2. Strength

    Time frame: 6, 12, and 24 weeks post surgery

    Changes in muscle strength from the start of rehabilitation to 6, 12, and 24 weeks following surgery between the two groups in the injured limb.

Sponsors and collaborators

Lead sponsor

University of Southern California

Other

Collaborators

  • Boston University
  • University of Oregon

Registry information

Official study title

The Effects of Acute Testosterone Administration in Men on Muscle Mass, Strength, and Physical Function Following ACL Reconstructive Surgery

Acronym: TACL

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
May 10, 2012
Registry last updated
Mar 2, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.